

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 68908

Title: Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Reviewer's code: 04244067

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Doctor

Reviewer's Country/Territory: Reviewer_Country

Author's Country/Territory: China

Manuscript submission date: 2021-06-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-09 02:45

Reviewer performed review: 2021-06-09 06:46

Review time: 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This manuscript provides sufficient information on recent preclinical and clinical studies to make it useful to the reader.

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 68908

Title: Combined Targeted Therapy and Immunotherapy for Cancer Treatment

Reviewer's code: 00863327

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Full Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: China

Manuscript submission date: 2021-06-08

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-10 03:12

Reviewer performed review: 2021-06-11 09:58

Review time: 1 Day and 6 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

It is an interesting review article exploring the recent progress in combined targeted therapies and immunotherapies for cancer treatment since rapid responses of the former can synergize with more durable responses of the latter. The authors also discussed the associated challenges of such combined therapies. The manuscript is well written in English and directly relevant to clinical application. There are two minor suggestions as follows. 1. Since the Table 1 is the only table in this article, in addition to targeted therapies, the authors should comprehensively demonstrate the detailed mechanisms for immunotherapies. For example, pembrolizumab targeting PD-1 on T cells, nivolumab targeting PD-L1 on tumor cells, etc. 2. There are some typographical errors needed to be corrected as follows. In title page, Combined rather than Combining Targeted Therapy and ---. In page 3 line 44, chemo- or radiation rather than chemo-or radiation ---. In page 11 line 250. anti-CTLA-4 antibodies rather than anti-CTLA4 antibodies ---.